Get the Stockscreener App
61.37
5.90%
-3.85
Tempus Ai Inc stock is traded at $61.37, with a volume of 15.45M.
It is down -5.90% in the last 24 hours and up +40.15% over the past month.
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
See More
Previous Close:
$65.22
Open:
$66.26
24h Volume:
15.45M
Relative Volume:
1.18
Market Cap:
$9.87B
Revenue:
$640.44M
Net Income/Loss:
$-743.28M
P/E Ratio:
-5.4364
EPS:
-11.2888
Net Cash Flow:
$-206.93M
1W Performance:
+7.55%
1M Performance:
+40.15%
6M Performance:
-16.81%
1Y Performance:
+0.00%
1-Day Range:
$60.50
$66.30
1-Week Range:
$48.71
$66.42
52-Week Range:
$22.89
$91.45
Tempus Ai Inc Stock (TEM) Company Profile
Name
Tempus Ai Inc
Sector
Industry
Phone
800-976-5448
Address
600 WEST CHICAGO AVENUE, CHICAGO
Compare TEM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TEM
Tempus Ai Inc
|
61.37 | 9.87B | 640.44M | -743.28M | -206.93M | -11.29 |
|
VEEV
Veeva Systems Inc
|
237.05 | 38.54B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
59.19 | 11.13B | 516.85M | 174.11M | 217.38M | 0.87 |
|
HQY
Healthequity Inc
|
90.40 | 7.83B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
40.01 | 7.04B | 906.14M | -52.62M | 89.62M | -0.3621 |
Tempus Ai Inc Stock (TEM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | BTIG Research | Buy |
| Feb-25-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-12-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-05-25 | Resumed | TD Cowen | Buy |
| Dec-13-24 | Initiated | Wolfe Research | Outperform |
| Dec-09-24 | Initiated | Guggenheim | Buy |
| Nov-11-24 | Downgrade | Stifel | Buy → Hold |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-12-24 | Initiated | Piper Sandler | Neutral |
| Jul-09-24 | Initiated | BofA Securities | Buy |
| Jul-09-24 | Initiated | JP Morgan | Overweight |
| Jul-09-24 | Initiated | Longbow | Buy |
| Jul-09-24 | Initiated | Loop Capital | Buy |
| Jul-09-24 | Initiated | Morgan Stanley | Overweight |
| Jul-09-24 | Initiated | Needham | Buy |
| Jul-09-24 | Initiated | Stifel | Buy |
| Jul-09-24 | Initiated | TD Cowen | Buy |
| Jul-09-24 | Initiated | William Blair | Outperform |
View All
Tempus Ai Inc Stock (TEM) Latest News
Jim Cramer Says Stay Away from This Nancy Pelosi Stock - MSN
These AI Stocks Posted Robust Results: Time to Buy? - Yahoo Finance
The Tempus AI, Inc. (NASDAQ:TEM) First-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st
Morgan Stanley raises Tempus AI price target to $65 from $60 - Investing.com Australia
Tempus AI Stock: Time to Double Down or Cut and Run? - MarketBeat
Tempus AI Stock: Time To Double Down Or Cut And Run? - Barchart.com
Why Tempus AI, Inc. (TEM) Skyrocketed On Wednesday - Insider Monkey
Why These 10 Stocks Soared Today - Insider Monkey
Tempus AI Rallies After Q1 Beat, Analyst Notes AI-Driven Platform And Expanding Pharma Deals - Benzinga
Tempus AI price target raised to $65 from $60 at BTIG - TipRanks
Global AI in Clinical Trials Market to Show Tremendous Growth at a CAGR of ~12% by 2032 | DelveInsight - GlobeNewswire Inc.
U.S. STOCKS ON THE MOVE-Bio-Techne, Johnson Controls, Tempus AI - TradingView
What’s Next For Tempus AI Stock? - Forbes
Tempus AI, Inc. (TEM): Among Most Popular Stocks on Robinhood in 2025 - Insider Monkey
Cathie Wood-Backed Tempus AI Says Pharma Contracts Solid Despite Biotech Funding Challenges, Tariff Pressures - Benzinga
Tempus AI Strikes $200M Deal With AstraZeneca, Pathos To Build World's Largest Oncology Model - Benzinga
Tempus AI Inc (TEM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Tempus: Q1 Earnings Snapshot - MySA
Earnings call transcript: Tempus AI Q1 2025: Revenue Surges, Stock Dips - Investing.com India
Tempus AI raises revenue guidance to $1.25B for 2025, supported by new $200M AstraZeneca deal - MSN
Tempus AI Inc Reports Q1 2025 Revenue of $255.7 Million and Net Loss of $68 Million - GuruFocus
On heels of big data deals, Tempus AI touts robust revenue - Crain's Chicago Business
Tempus AI beats Q1 expectations, raises 2025 outlook; shares dip 2.3% - Investing.com Nigeria
Tempus AI Q1 2025 slides: revenue surges 75%, approaching EBITDA profitability - Investing.com India
Tempus AI Q1 Non-GAAP Loss Narrows; Revenue Rises; Slightly Ups Full Year Guidance - marketscreener.com
Tempus AI reports Q1 adjusted EPS (24c), consensus (27c) - TipRanks
Earnings Flash (TEM) Tempus AI Reports Q1 Revenue $255.7M, vs. FactSet Est of $248.1M - marketscreener.com
Tempus Reports First Quarter 2025 Results - Bluefield Daily Telegraph
Tempus AI Stock Dips as Earnings on Deck (NASDAQ: TEM) – What To Expect - AskTraders.com
Tempus selects TIME Network for Phase I clinical trials - MSN
TEMPUS (Nasdaq: TEM) Earnings: Live Coverage And What to Expect - AOL.com
tempus AI Inc Class A call volume above normal and directionally bullish - TipRanks
Tempus AI (Nasdaq: TEM) Earnings: Live Coverage And What to Expect - 24/7 Wall St.
Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time. - AOL.com
Jim Cramer Warns on Tempus AI (TEM): “Diagnostics With no Dough? I’m Out” - Insider Monkey
AI Healthcare Boom Gains Speed as Regulators and Innovators Align - The Globe and Mail
Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry - Business Wire
Tempus AI Shows Rising Price Performance With Jump To 92 RS Rating - Investor's Business Daily
Tempus exec-founded Pathos AI launched a $400M funding round. It's already filling up. - Crain's Chicago Business
Pathos AI gets AstraZeneca funding as biotech plans to raise up to $400M - Endpoints News
AI-Powered Imaging Diagnostics Market: Growth, Trends & - openPR.com
Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment - Business Wire
Is This the Best Nancy Pelosi Stock to Buy After a 40% Pullback? - The Globe and Mail
Tempus AI Stock Surges 43% in Q1: Buy Now or Wait for Earnings? - MSN
‘NextGen’ Tempus AI Workers Continue to Make History with Landmark First IAM Contract - IAM Union
Tempus AI publishes xF+ assay study results in Journal of Molecular Diagnostics - TipRanks
Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection - The Joplin Globe
Tempus Ai Inc Stock (TEM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):